Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Wesseling

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Plos One|May 12, 2016
Correction: Bone Canopies in Pediatric Renal OsteodystrophyRenata C Pereira, Thomas L Andersen, Peter A Friedman, et al.
JBMR Plus|April 7, 2026
Impaired bone matrix maturation and mineralization are prevalent in adolescent end-stage kidney diseaseNadja Fratzl-Zelman, Renata C Pereira, Stéphane Blouin, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2009
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically activeTakashi Shimada, Itaru Urakawa, Tamara Isakova, et al.
Pediatric Nephrology (Berlin, Germany)|April 27, 2021
Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipientsBlair Limm-Chan, Katherine Wesseling-Perry, Meghan H Pearl, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 7, 2013
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysisJoshua Zaritsky, Anjay Rastogi, George Fischmann, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 17, 2010
Value of the new bone classification system in pediatric renal osteodystrophySevcan A Bakkaloglu, Katherine Wesseling-Perry, Renata C Pereira, et al.
Kidney International|September 24, 2010
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidismKatherine Wesseling-Perry, Renata C Pereira, Shobha Sahney, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 6, 2013
The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trialJustine Bacchetta, Katherine Wesseling-Perry, Beatriz Kuizon, et al.
The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysisKatherine Wesseling-Perry, Renata C Pereira, Hejing Wang, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2016
Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot StudyVille-Valtteri Välimäki, Outi Mäkitie, Renata Pereira, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Plos One|May 12, 2016
Correction: Bone Canopies in Pediatric Renal OsteodystrophyRenata C Pereira, Thomas L Andersen, Peter A Friedman, et al.
JBMR Plus|April 7, 2026
Impaired bone matrix maturation and mineralization are prevalent in adolescent end-stage kidney diseaseNadja Fratzl-Zelman, Renata C Pereira, Stéphane Blouin, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2009
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically activeTakashi Shimada, Itaru Urakawa, Tamara Isakova, et al.
Pediatric Nephrology (Berlin, Germany)|April 27, 2021
Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipientsBlair Limm-Chan, Katherine Wesseling-Perry, Meghan H Pearl, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 7, 2013
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysisJoshua Zaritsky, Anjay Rastogi, George Fischmann, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 17, 2010
Value of the new bone classification system in pediatric renal osteodystrophySevcan A Bakkaloglu, Katherine Wesseling-Perry, Renata C Pereira, et al.
Kidney International|September 24, 2010
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidismKatherine Wesseling-Perry, Renata C Pereira, Shobha Sahney, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 6, 2013
The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trialJustine Bacchetta, Katherine Wesseling-Perry, Beatriz Kuizon, et al.
The Journal of Clinical Endocrinology and Metabolism|December 4, 2008
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysisKatherine Wesseling-Perry, Renata C Pereira, Hejing Wang, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2016
Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot StudyVille-Valtteri Välimäki, Outi Mäkitie, Renata Pereira, et al.
Pageof 7